ClinicalTrials.gg
RecruitingNCT07486401BEAMUpdated Mar 20, 2026

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

An interventional study of Biomarker-directed treatment for asthma management and Usual Care in Asthma Exacerbations, Biomarkers / Blood and Eosinophil Blood Count, sponsored by National Healthcare Group Polyclinics. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by National Healthcare Group Polyclinics · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Asthma with a site in Singapore — 3 open to participants now, 3 under way, 1 of them phase 3. Asthma · Singapore.

Planned enrollment
11th of 19
240 · median 253
Started
2025
with 1 other
No phase
5 of 25
1 open now
Registered
24th of 25
by date

Among the 25 studies in Asthma with a site in Singapore, this one is the 11th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 with no phase, and was the 24th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 25 studies in Asthma with a site in Singapore are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Asthma with a site in Singapore, or all of them as a file.
02

Study summary

The aim of this study is to evaluate usual care versus biomarker-directed care (using blood eosinophil counts) for the management of asthma patients in primary care setting.

The study hypothesizes that BEC is a valuable biomarker that can guide asthma treatment, and result in reduction in asthma exacerbations, better symptom control and improvement in quality of life compared to usual arm in mild to moderate asthma patients in the primary care setting.

Researchers would compare using blood eosinophil count guided to usual care to see if biomarker-directed asthma treatment and management

03

Conditions studied

  • Asthma Exacerbations
  • Biomarkers / Blood
  • Eosinophil Blood Count

Browse trials for

Keywords

  • Asthma
  • Mild-moderate Asthma
  • Blood Biomarkers
  • Eosinophil
  • Primary Care
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Singaporeans or Singapore Permanent Residents
  2. Patients aged ≥21 to 65 years old
  3. Physician diagnosed asthma for duration of at least 4 weeks
  4. On or will be initiated on Global Initiative for Asthma (GINA) 2025 step 1-3) treatment
  5. No asthma exacerbations* in the preceding 4 weeks before randomisation
  6. Able and willing to attend study appointments approximately every 4-monthly over a 1-year period
  7. Able to provide
  8. Stable cardiovascular status (i.e. controlled hypertension, no active symptoms of heart disease or arrhythmias) *Exacerbations are defined as worsening of asthma symptoms requiring systemic for 3 or more days, emergency department visit, or hospitalization

Exclusion criteria

Exclusion Criteria:

  1. History of life-threatening asthma requiring intubation or intensive care unit admission
  2. Severe asthma or difficult to treat asthma
  3. Current use of long-term , LTRA receptor antagonist (Montelukast) and Theophylline or long-term oral
  4. Presence of other known causes of eosinophilia besides asthma (e.g. parasitic infection), based on physician's discretion and investigation as per clinical practice and suspicion
  5. Current use of beta-blocking agents including eye-drops
  6. Use of oral, rectal, or parenteral glucocorticoid within 30 days and/or depot parenteral glucocorticoid within 12 weeks prior to recruitment
  7. Known diagnosis of , Interstitial lung disease or bronchiectasis
  8. Any significant disease or disorder (eg. Cardiovascular, pulmonary other than asthma, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate in the study
  9. Current enrolment in other interventional clinical trial for asthma
  10. Female subjects who are pregnant or planning pregnancy during the study period
  11. Planned travel outside of the country for ≥16 consecutive weeks during the study
  12. Investigator's assessment of poor capability of following study instructions or comply with study procedures
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Active comparator
    Biomarker-Directed Arm

    Asthma management and treatment for participants in this group will be guided by blood eosinophil count (biomarker-directed).

    Diagnostic Test: Biomarker-directed treatment for asthma management

  • Other
    Control Arm (Usual Care)

    Participants in the control arm will receive usual care, this does not involve the use of blood eosinophils

    Other: Usual Care

Interventions

  • Diagnostic testBiomarker-directed treatment for asthma management

    Asthma management and treatment for participants in this group will be guided by blood eosinophil count (biomarker-directed).

  • OtherUsual Care

    Participants in this arm will receive usual asthma care in primary care that does not involve the use of blood eosinophils

06

What researchers measure

Primary outcomes

  1. Time to first asthma exacerbation requiring hospitalisation

    Time to first asthma exacerbation requiring hospitalisation comparing usual care vs biomarker-directed care measured in days.

    Time frame: Within 12 months from enrollment

  2. Number of asthma exacerbations not requiring hospitalisation

    Number of asthma exacerbations not requiring hospitalisation comparing usual care vs biomarker-directed care measured via counts.

    Time frame: From enrollment to 12 months

  3. Worsening of asthma symptoms

    Worsening of asthma symptoms based on Asthma Control Test Score (ACT score decrease ≥3 points from baseline) comparing usual care vs biomarker-directed care measured based on scores and percentage of scores.

    Time frame: From enrollment to 12 months

Secondary outcomes

  1. Asthma exacerbations requiring systemic corticosteroids and urgent healthcare visits

    Asthma exacerbations requiring systemic corticosteroids and urgent healthcare visits (outpatient, ED, admissions) measured via counts.

    Time frame: From enrollment to 12 months

  2. Change in Asthma Quality of Life Questionnaire score

    Change in asthma quality of life questionnaire (AQLQ) score from baseline measure via score points ranging from 1-7, with higher scores indicating better quality of life.

    Time frame: From enrollment to 12 months

  3. Change in Asthma Control Test score

    Change in Asthma Control Test (ACT) scores from baseline measure via score points ranging from 5-25, with higher scores indicating better asthma control.

    Time frame: From enrollment to 12 months

  4. Change in Global Initiative for Asthma score

    Change in Global Initiative for Asthma (GINA) scores from baseline measure via score points ranging from 0-4, with lower scores indicating better asthma control.

    Time frame: From enrollment to 12 months

  5. Changes in Forced Expiratory Volume in 1 second

    Changes in Forced Expiratory Volume in 1 second (FEV1) from spirometry test, measured in litres, percentages and litres per second. Lower FEV1 value indicates lung obstruction.

    Time frame: From enrollment to 12 months

  6. Changes in Forced Vital Capacity

    Changes in Forced Vital Capacity (FVC) from spirometry test, measured in litres, percentages and litres per second. Lower FVC value indicates lung obstruction.

    Time frame: From enrollment to 12 months

  7. Changes in Forced Expiratory Volume in 1 second/Forced Vital Capacity Ratio

    Changes in Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio from spirometry test, measured in litres, percentages and litres per second. FEV1/FVC below 0.70 typically indicates airway obstruction.

    Time frame: From enrollment to 12 months

  8. Changes in Peak Expiratory Flow

    Changes in Peak Expiratory Flow (PEF) from spirometry test, measured in litres, percentages and litres per second. Higher PEF value indicates good asthma control.

    Time frame: From enrollment to 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.

Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 36 months is above that.

Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2025
First posted
Mar 20, 2026
StartActual
Dec 3, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07486401
Lead sponsor
National Healthcare Group Polyclinics
Collaborators
National Medical Research Council (NMRC), Singapore, Singapore General Hospital
Responsible party
Wern Ee Tang (Family Physician, Senior Consultant, National Healthcare Group Polyclinics) — Principal investigator
First posted
Mar 20, 2026
Start date
Dec 3, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Mar 20, 2026

Study contacts

Wern Ee Tang
Contact
wern.ee.tang@nhghealth.com.sg
(65) 6355 3000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion